Alvotech recruit new CEO from within

pharmafile | August 9, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alvotech, biotech, drugs, pharma, pharmaceutical 

Alvotech, a biopharmaceutical company focusing on the development and manufacture of based in Reykjavik, Iceland, has replaced outgoing CEO, Eef Schimmelpennink, with Rasmus Rojkjaer. The company has only existed since 2013, after being spun out of Alvogen, and Rojkjaer has only recently joined the company.

Rojkjaer has been with Alvotech since 2016, and previously performed the role of Chief Operating Officer. Before his time at Alvotech, Rojkjaer had plenty of experience working at Novo Nordisk, as a Senior Director, and as Chairman of the Board at Mylan.

He is tasked with creating a global market leader in biogenerics through the development of high quality and cost-controlled biosimilar products. He will be expected to tap into his experience with Mylan for this project, where he created and led the establishment of its biosimilar strategy. Rojkjaer will also join the executive board at Alvogen.

Robert Wessman, Alvotech’s Chairman and founder, said: “Rasmus has been an integral part of Alvotech‘s management team since joining us in 2016 as Chief Operating Officer, and we are fortunate to have someone with his experience to lead our biosimilar business going forward. The company has achieved many important milestones since its launch in 2013. Now, as Alvotech enters the next phase, Eef will be leaving to take on new ventures. On behalf of the Board and management team, I would like to thank Eef for his contributions to Alvotech.”

Related Content

Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada

Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content